Quizlet
or
There are no sets in this subject.
No groups found.
| omalizumab definitions | |||
|---|---|---|---|
| # | Definition | Sets | |
| 1 | antiasthma; ab against ige -> prev ige from binding mast cells, basophils -> prev degran/release if inflamm med, decr fcer1; requires >90% reductn of ige for eff; ade: inj rxn, ha, itch | 2 sets | |
| 2 | immunomodulator; rna derived antibody | 1 set | |
| 3 | ige, asthma | 1 set | |
| 4 | (b.n.); xolair | 1 set | |
| 5 | xolair | 1 set | |
| 6 | antagonist to mast cell binding with ige | 1 set | |
| 7 | toxicity: injection site, anaphylactic reactions, increased risk of heart disorders | 1 set | |
| 8 | antibody against fc region of ige | 1 set | |
| 9 | inds cre3 region of ige, lowers free serum ige, reduces amt of ige bound to mast cells, binding of cre3 by anti-ige keeps ige from biding feri, reduces number of fceri | 1 set | |
| 10 | a monoclonal antibody that binds ige; not a first line treatment | 1 set | |
| 11 | ige antibody-based drug | 1 set | |
| 12 | sc injection; approved for asthma only! | 1 set | |
| 13 | asthma, anti-inflammatory agents, anti-ige therapy | 1 set | |
| 14 | control med for patients with severe asthma that has an allergic component, usually given when other drugs fail to control the asthma | 1 set | |
| 15 | anti-ige ab that reduces release of mediators from mast cells and basos; subq every 2-4 weeks; for asthma and rhinitis | 1 set | |
| 16 | allergy/ asthma suppression by binding ige thus preventing it from binding to fc receptors on mast cells decreasing likeliness of hyperreactive mast cells | 1 set | |
| 17 | anti- ige agent | 1 set | |
| 18 | asthma; anti-inflammatory agents; anti-ige therapy | 1 set | |